FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090355867> ?p ?o ?g. }

• W3090355867 endingPage "1568" @default.
• W3090355867 startingPage "1564" @default.
• W3090355867 abstract "Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenic BRAFV600 in melanoma1,2. We conducted S1320, a randomized, open-label, phase 2 clinical trial (NCT02196181) evaluating whether intermittent dosing of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib improves progression-free survival in patients with metastatic and unresectable BRAFV600 melanoma. Patients were enrolled at 68 academic and community sites nationally. All patients received continuous dabrafenib and trametinib during an 8-week lead-in period, after which patients with non-progressing tumors were randomized to either continuous or intermittent dosing of both drugs on a 3-week-off, 5-week-on schedule. The trial has completed accrual and 206 patients with similar baseline characteristics were randomized 1:1 to the two study arms (105 to continuous dosing, 101 to intermittent dosing). Continuous dosing yielded a statistically significant improvement in post-randomization progression-free survival compared with intermittent dosing (median 9.0 months versus 5.5 months, P = 0.064, pre-specified two-sided α = 0.2). Therefore, contrary to the initial hypothesis, intermittent dosing did not improve progression-free survival in patients. There were no differences in the secondary outcomes, including overall survival and the overall incidence of treatment-associated toxicity, between the two groups." @default.
• W3090355867 created "2020-10-08" @default.
• W3090355867 creator A5003474421 @default.
• W3090355867 creator A5010020568 @default.
• W3090355867 creator A5023066362 @default.
• W3090355867 creator A5026465769 @default.
• W3090355867 creator A5028772063 @default.
• W3090355867 creator A5029053875 @default.
• W3090355867 creator A5034792001 @default.
• W3090355867 creator A5045110376 @default.
• W3090355867 creator A5051439028 @default.
• W3090355867 creator A5053441903 @default.
• W3090355867 creator A5053602981 @default.
• W3090355867 creator A5054617686 @default.
• W3090355867 creator A5056665543 @default.
• W3090355867 creator A5060838528 @default.
• W3090355867 creator A5070553718 @default.
• W3090355867 creator A5072582710 @default.
• W3090355867 creator A5073549408 @default.
• W3090355867 creator A5083745558 @default.
• W3090355867 creator A5085936753 @default.
• W3090355867 creator A5090012826 @default.
• W3090355867 date "2020-10-01" @default.
• W3090355867 modified "2023-10-06" @default.
• W3090355867 title "Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial" @default.
• W3090355867 cites W1995559542 @default.
• W3090355867 cites W2032211985 @default.
• W3090355867 cites W2040286515 @default.
• W3090355867 cites W2043058822 @default.
• W3090355867 cites W2058390096 @default.
• W3090355867 cites W2100614336 @default.
• W3090355867 cites W2105660237 @default.
• W3090355867 cites W2106543129 @default.
• W3090355867 cites W2160766792 @default.
• W3090355867 cites W2297167225 @default.
• W3090355867 cites W2491982852 @default.
• W3090355867 cites W2587429794 @default.
• W3090355867 cites W2591615675 @default.
• W3090355867 cites W2735449222 @default.
• W3090355867 cites W2746822858 @default.
• W3090355867 cites W2752569532 @default.
• W3090355867 cites W2755929010 @default.
• W3090355867 cites W2773413889 @default.
• W3090355867 cites W2891205725 @default.
• W3090355867 cites W2996923528 @default.
• W3090355867 doi "https://doi.org/10.1038/s41591-020-1060-8" @default.
• W3090355867 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8063889" @default.
• W3090355867 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33020646" @default.
• W3090355867 hasPublicationYear "2020" @default.
• W3090355867 type Work @default.
• W3090355867 sameAs 3090355867 @default.
• W3090355867 citedByCount "61" @default.
• W3090355867 countsByYear W30903558672020 @default.
• W3090355867 countsByYear W30903558672021 @default.
• W3090355867 countsByYear W30903558672022 @default.
• W3090355867 countsByYear W30903558672023 @default.
• W3090355867 crossrefType "journal-article" @default.
• W3090355867 hasAuthorship W3090355867A5003474421 @default.
• W3090355867 hasAuthorship W3090355867A5010020568 @default.
• W3090355867 hasAuthorship W3090355867A5023066362 @default.
• W3090355867 hasAuthorship W3090355867A5026465769 @default.
• W3090355867 hasAuthorship W3090355867A5028772063 @default.
• W3090355867 hasAuthorship W3090355867A5029053875 @default.
• W3090355867 hasAuthorship W3090355867A5034792001 @default.
• W3090355867 hasAuthorship W3090355867A5045110376 @default.
• W3090355867 hasAuthorship W3090355867A5051439028 @default.
• W3090355867 hasAuthorship W3090355867A5053441903 @default.
• W3090355867 hasAuthorship W3090355867A5053602981 @default.
• W3090355867 hasAuthorship W3090355867A5054617686 @default.
• W3090355867 hasAuthorship W3090355867A5056665543 @default.
• W3090355867 hasAuthorship W3090355867A5060838528 @default.
• W3090355867 hasAuthorship W3090355867A5070553718 @default.
• W3090355867 hasAuthorship W3090355867A5072582710 @default.
• W3090355867 hasAuthorship W3090355867A5073549408 @default.
• W3090355867 hasAuthorship W3090355867A5083745558 @default.
• W3090355867 hasAuthorship W3090355867A5085936753 @default.
• W3090355867 hasAuthorship W3090355867A5090012826 @default.
• W3090355867 hasBestOaLocation W30903558672 @default.
• W3090355867 hasConcept C121608353 @default.
• W3090355867 hasConcept C126322002 @default.
• W3090355867 hasConcept C143998085 @default.
• W3090355867 hasConcept C168563851 @default.
• W3090355867 hasConcept C184235292 @default.
• W3090355867 hasConcept C204243189 @default.
• W3090355867 hasConcept C2776131300 @default.
• W3090355867 hasConcept C2776694085 @default.
• W3090355867 hasConcept C2777288759 @default.
• W3090355867 hasConcept C2777658100 @default.
• W3090355867 hasConcept C2778472372 @default.
• W3090355867 hasConcept C2778830669 @default.
• W3090355867 hasConcept C2780739268 @default.
• W3090355867 hasConcept C2781249067 @default.
• W3090355867 hasConcept C2994587330 @default.
• W3090355867 hasConcept C502942594 @default.
• W3090355867 hasConcept C535046627 @default.
• W3090355867 hasConcept C57074206 @default.
• W3090355867 hasConcept C71924100 @default.
• W3090355867 hasConcept C86803240 @default.

• next